المؤلفون: Lake, Jordan E, Wang, Ruibin, Barrett, Benjamin W, Bowman, Emily, Hyatt, Ana N, Debroy, Paula, Candelario, Jury, Teplin, Linda, Bodnar, Kaitlin, McKay, Heather, Plankey, Michael, Brown, Todd T, Funderburg, Nicholas, Currier, Judith S

المصدر: AIDS. 36(13)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, Cardiovascular, HIV/AIDS, Infectious Diseases, Good Health and Well Being, 1-Alkyl-2-acetylglycerophosphocholine Esterase, Adult, Biomarkers, Cardiovascular Diseases, Cohort Studies, Endothelins, Female, HIV Infections, Hormones, Humans, Inflammation, Interleukin-6, Interleukin-8, Lipopolysaccharide Receptors, Lipoproteins, LDL, Male, Middle Aged, P-Selectin, Plasminogen Activator Inhibitor 1, Receptor for Advanced Glycation End Products, von Willebrand Factor, cardiovascular biomarkers, feminizing hormonal therapy, HIV, trans women, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences

الوصف: BackgroundFeminizing hormonal therapy (FHT) and HIV potentially alter cardiovascular disease (CVD) risk in transgender women (TW).MethodsTW were enrolled in Los Angeles, California and Houston, Texas and frequency-matched to Multicenter AIDS Cohort Study cisgender men (CM) on age, race, substance use, and abacavir use. Biomarkers of CVD risk and inflammation were assessed via ELISA. Wilcoxon rank sum and Fisher's exact tests compared TW and CM. Multivariable linear regression assessed factors associated with biomarker concentrations.ResultsTW (HIV+ n  = 75, HIV- n  = 47) and CM (HIV+ n  = 40, HIV- n  = 40) had mean age 43-45 years; TW/CM were 90%/91% non-Hispanic Black, Hispanic, or Multiracial, 26%/53% obese, and 34%/24% current smokers; 67% of TW were on FHT. Among people with HIV (PWH), TW had higher median extracellular newly-identified receptor for advanced glycation end-products (EN-RAGE), lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), soluble tumor necrosis factor receptor type (sTNFR) I/II, interleukin (IL)-8 and plasminogen activator inhibitor (PAI)-1, but lower soluble CD14, von Willebrand factor (vWF) and endothelin (ET)-1 levels than CM. Findings were similar for participants without HIV (all P

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7842k8nbTest

المؤلفون: Lake, Jordan E, Hyatt, Ana N, Feng, Han, Debroy, Paula, Kettelhut, Aaren, Miao, Hongyu, Peng, Liming, Bhasin, Shalender, Bell, Susan, Rianon, Nahid, Brown, Todd T, Funderburg, Nicholas T

المساهمون: National Institutes of Health, Gilead Sciences, Principal Investigator

المصدر: Open Forum Infectious Diseases ; volume 10, issue 4 ; ISSN 2328-8957

مصطلحات موضوعية: Infectious Diseases, Oncology

الوصف: Background Cardiometabolic disease in transgender women (TW) is affected by gender-affirming hormonal therapies (GAHTs), HIV, and antiretroviral therapy (ART). We evaluated the 48-week safety/tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs continued ART in TW on GAHT. Methods TW on GAHT and suppressive ART were randomized 1:1 to switch to B/F/TAF (Arm A) or continue current ART (Arm B). Cardiometabolic biomarkers, sex hormones, bone mineral density (BMD) and lean/fat mass by DXA scan, and hepatic fat (controlled continuation parameter [CAP]) were measured. Wilcoxon rank-sum/signed-rank and χ2 tests compared continuous and categorical variables. Results TW (Arm A n = 12, Arm B n = 9) had a median age of 45 years. Ninety-five percent were non-White; 70% were on elvitegravir or dolutegravir, 57% TAF, 24% abacavir, and 19% TDF; 29% had hypertension, 5% diabetes, and 62% dyslipidemia. There were no adverse events. Arm A/B had 91%/89% undetectable HIV-1 RNA at week 48 (w48). Baseline (BL) osteopenia (Arm A/B 42%/25%) and osteoporosis (17%/13%) were common, without significant changes. BL lean/fat mass were similar. At w48, Arm A had stable lean mass but increased limb (3 lbs) and trunk (3 lbs) fat (within-arm P < .05); fat in Arm B remained stable. No changes occurred in lipid or glucose profiles. Arm B had a greater w48 decrease (−25 vs −3 dB/m; P = .03) in CAP. BL and w48 concentrations of all biomarkers were similar. Conclusions In this cohort of TW, switch to B/F/TAF was safe and metabolically neutral, though greater fat gain occurred on B/F/TAF. Further study is needed to better understand cardiometabolic disease burden in TW with HIV.

الإتاحة: https://doi.org/10.1093/ofid/ofad178Test
https://academic.oup.com/ofid/article-pdf/10/4/ofad178/50066137/ofad178.pdfTest

المؤلفون: Lake, Jordan E., Miao, Hongyu, Bowman, Emily R., Clark, Jesse L., Hyatt, Ana N., Kettelhut, Aaren, Lama, Javier R., Reisner, Sari L., Mayer, Kenneth H., Perez‐Brumer, Amaya, Funderburg, Nicholas

المصدر: HIV Medicine; Nov2023, Vol. 24 Issue 11, p1144-1149, 6p

مصطلحات موضوعية: CARDIOVASCULAR diseases risk factors, TRANS women, RESEARCH funding, HIGH density lipoproteins, LONGITUDINAL method, HIV, INSULIN resistance

مستخلص: Objectives: Gender‐affirming hormonal therapies (GAHT) and HIV increase cardiovascular risk for transgender women (TW), yet there is a paucity of data quantifying cardiometabolic changes following GAHT initiation, particularly among TW with HIV. Methods: The Féminas study enrolled TW from October 2016 to March 2017 in Lima, Peru. Participants reported sexual activity that was high risk for HIV acquisition or transmission. All were tested for HIV/ sexually transmitted infection and were given access to GAHT (oestradiol valerate and spironolactone), HIV pre‐exposure prophylaxis (PrEP) or antiretroviral therapy (ART) for 12 months. Biomarker measurement was done on stored serum, whereas fasting glucose and lipids were measured in real time. Results: In all, 170 TW (32 with HIV, 138 without HIV) had median age 27 years and 70% prior GAHT use. At baseline, PCSK9, sCD14, sCD163, IL‐6, sTNFRI/II, CRP and EN‐RAGE levels were significantly higher in TW with HIV than in TW without HIV. High‐density lipoprotein and total cholesterol were lower and insulin and glucose parameters were similar. All TW with HIV started ART, but only five achieved virological suppression at any time. No TW without HIV initiated PrEP. Over 6 months, all participants initiated GAHT and had worsening insulin, glucose and HOMA‐IR. Large d‐dimer decreases also occurred. Similar changes occurred in TW with and without HIV. Conclusions: In this unique cohort of TW, GAHT decreased d‐dimer but worsened insulin sensitivity. Because PrEP uptake and ART adherence were very low, observed effects are primarily attributed to GAHT use. Further study is needed to better understand cardiometabolic changes in TW by HIV serostatus. [ABSTRACT FROM AUTHOR]

: Copyright of HIV Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Lake, Jordan E., Hyatt, Ana N., Feng, Han, Miao, Hongyu, Somasunderam, Anoma, Utay, Netanya S., Corey, Kathleen E.

المصدر: Transgender Health ; ISSN 2688-4887 2380-193X

مصطلحات موضوعية: Medicine (miscellaneous), Gender Studies

الإتاحة: https://doi.org/10.1089/trgh.2022.0182Test

المؤلفون: Hyatt, Ana N., Lake, Jordan E.

المصدر: Current HIV/AIDS Reports ; volume 19, issue 5, page 415-424 ; ISSN 1548-3568 1548-3576

مصطلحات موضوعية: Infectious Diseases, Virology

الإتاحة: https://doi.org/10.1007/s11904-022-00620-2Test